March 27, 2018 / 7:21 AM / 4 months ago

BRIEF-Shield Therapeutics Says ‍Receives EU Commission Approval For Broadening Of Indication For Feraccru To Treatment Of Iron Deficiency In Adults​

March 27 (Reuters) - Shield Therapeutics Plc:

* SHIELD THERAPEUTICS - ‍RECEIVES EU COMMISSION APPROVAL FOR BROADENING OF INDICATION FOR FERACCRU TO TREATMENT OF IRON DEFICIENCY IN ADULTS​

* SHIELD THERAPEUTICS - ‍EC ADOPTED DECISION TO EXTEND APPROVED INDICATION FOR FERACCRU TO INCLUDE TREATMENT OF ALL ADULTS WITH IRON DEFICIENCY OR WITHOUT ANAEMIA​

* SHIELD THERAPEUTICS- ‍EUROPEAN COMMISSION APPROVAL GOVERNS MARKETING OF FERACCRU IN ALL 28 EU MEMBER COUNTRIES, AS WELL AS ICELAND, NORWAY AND LIECHTENSTEIN​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below